Literature DB >> 12470137

Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion.

Shelley R Boyd1, Ian Zachary, Usha Chakravarthy, George J Allen, G Brian Wisdom, Ian A Cree, John F Martin, Philip G Hykin.   

Abstract

OBJECTIVE: To establish a role for vascular endothelial growth factor (VEGF) during the onset and clinical course of neovascularization of the iris (NVI) in ischemic central retinal vein occlusion.
METHODS: Sixteen patients with ischemic central retinal vein occlusion were followed up for 12 months by clinical examination, retinal and iris angiography, and serial anterior chamber sampling of aqueous humor. Aqueous VEGF level was determined by enzyme-linked immunoassay, and permeability changes were estimated by capillary zone electrophoretic assessment of aqueous albumin.
RESULTS: A correlation was found between aqueous VEGF concentrations and the onset, persistence, and regression of NVI; extent of retinal capillary nonperfusion; and vascular permeability. The NVI occurred when aqueous VEGF concentrations were 849 to 1569 pg/mL and regressed fully when they fell below 550 pg/mL. Aqueous concentrations of serum albumin, a marker of increased permeability, correlated with increased VEGF. Placental growth factor was found at low levels only when VEGF levels exceeded 330 pg/mL. The NVI remained VEGF-dependent during the course of the disease, regressing only if VEGF concentrations were reduced after laser ablation of hypoxic retina.
CONCLUSIONS: The close temporal correlation between aqueous VEGF levels and the course of neovascularization and permeability in human ischemic central retinal vein occlusion indicates that increased aqueous VEGF level may predict the need for treatment, and that anti-VEGF therapy at an early stage of ischemic central retinal vein occlusion may be therapeutically beneficial.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12470137     DOI: 10.1001/archopht.120.12.1644

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  59 in total

Review 1.  Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion.

Authors:  Tasanee Braithwaite; Afshan A Nanji; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab.

Authors:  L C Olmos; M S Sayed; A L Moraczewski; S J Gedde; P J Rosenfeld; W Shi; W J Feuer; R K Lee
Journal:  Eye (Lond)       Date:  2015-12-18       Impact factor: 3.775

Review 3.  Vascular endothelial growth factor biology: clinical implications for ocular treatments.

Authors:  R B Bhisitkul
Journal:  Br J Ophthalmol       Date:  2006-12       Impact factor: 4.638

Review 4.  Neovascular glaucoma.

Authors:  Sohan Singh Hayreh
Journal:  Prog Retin Eye Res       Date:  2007-08-08       Impact factor: 21.198

5.  Role of vascular endothelial growth factor in the breakdown of the blood-aqueous barrier after retinal laser photocoagulation in pigmented rabbits.

Authors:  Muh-Shy Chen; Ching-Chung Chang; Chang-Ping Lin; Peng-Chen Wang; Li-Rong Lin; Ping-Kang Hou; Tzyy-Chang Ho
Journal:  J Ocul Pharmacol Ther       Date:  2011-10-19       Impact factor: 2.671

6.  Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits.

Authors:  Lea Scheppke; Edith Aguilar; Ray F Gariano; Ruth Jacobson; John Hood; John Doukas; Jon Cao; Glenn Noronha; Shiyin Yee; Sara Weis; Michael B Martin; Richard Soll; David A Cheresh; Martin Friedlander
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

7.  Potential anti-vascular endothelial growth factor therapies for central retinal vein occlusion.

Authors:  Marta S Figueroa; Inés Contreras
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

8.  Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion.

Authors:  Juan Carlos Mesa Gutiérrez; Luis Arias Barquet; Josep Maria Caminal; Sergi Prades Almolda; Nùria Planas Domènech; Octavi Pujol Goita; Marc Rubio Caso; Jorge Arruga Ginebreda
Journal:  Clin Ophthalmol       Date:  2008-12

9.  Retinal vein occlusion: pathophysiology and treatment options.

Authors:  Niral Karia
Journal:  Clin Ophthalmol       Date:  2010-07-30

10.  Silver nanoparticles inhibit VEGF-and IL-1beta-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells.

Authors:  Sardarpasha Sheikpranbabu; Kalimuthu Kalishwaralal; Deepak Venkataraman; Soo Hyun Eom; Jongsun Park; Sangiliyandi Gurunathan
Journal:  J Nanobiotechnology       Date:  2009-10-30       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.